MERCK & CO Aktie

 

Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore....

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16....

Merck & Co will den Antikörper Tulisokibart nach positiven Phase-2b-Daten in die finale Phase 3 bringen. In einer Studie mit 149 Patienten mit mittelschwerer bis schwerer Hidradenitis suppurativa (HS) erreichte das Mittel nach 16 Wochen laut Ergebnissen vom August die primären und sekundären Endpunkte....

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brough...

MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation....

Die Aktie des US-Pharma-Konzerns Merck & Co befindet sich in bestechender Form. Kurzfristig angetrieben durch den Forschungserfolg mit Moderna bei einem personalisierten Hautkrebsimpfstoff, steht der eher defensive Titel vor neuen Rekorden....

FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use....

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue....

KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK), an American multinational pharmaceutical company, announced on Monday that it has entered into an exclusive global license agreement with SciBr......

Vor wenigen Wochen haben der Pharma-Riese Merck & Co und der Entwicklungspartner Moderna mit positiven Ergebnissen zu einem personalisierten Hautkrebsimpfstoff für Schlagzeilen gesorgt. Doch die Pipeline des im Dow Jones gelisteten Konzerns hat weitaus mehr zu bieten als den Bereich der Onkologie....

In the latest trading session, Merck (MRK) closed at $148.08, marking a -1.88% move from the previous day....

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?...

AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table....

MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced the Ministry of Health, Labor and Welfare in Japan has approved KEYTRUDA QLEX injection for subcutaneous use for all indications approved in Japan......

KENILWORTH (NJ) (dpa-AFX) - Drug major Merck & Co., Inc. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive o......

Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day....

London (www.aktiencheck.de) - Merck & Co-Aktienanalyse von HSBC: Die Analysten von HSBC erhöhen das Kursziel für die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) von 150 USD auf 172 USD und bestätigen das Rating "buy". HSBC habe die Kursziele innerhalb des Gesundheitssektors angepasst, um einer niedrigeren Risikoprämie für den Sektor sowie aktuellen Entwicklungen in den Produktpipelines Rechnung zu tragen. [mehr]...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....